文章：

急性髓系白血病移植后维持治疗

Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia

原文发布日期：26 May 2024

DOI: 10.3390/cancers16112015

类型: Article

开放获取: 是

英文摘要：

Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for patients with acute myeloid leukemia (AML). However, the post-transplant relapse rate ranges from 40 to 70%, particularly with reduced intensity conditioning, and remains a major cause of treatment failure for these patients due to the limited efficacy of salvage therapy options. Strategies to mitigate this risk are urgently needed. In the past few years, the basic framework of post-transplant maintenance has been shaped by several clinical trials investigating targeted therapy, chemotherapy, and immunomodulatory therapies. Although the practice of post-transplant maintenance in AML has become more common, there remain challenges regarding the feasibility and efficacy of this strategy. Here, we review major developments in post-transplant maintenance in AML, along with ongoing and future planned studies in this area, outlining the limitations of available data and our future goals.

摘要翻译： 

异基因造血细胞移植（allo-HCT）对于急性髓系白血病（AML）患者具有潜在治愈可能。然而，移植后复发率高达40%至70%，尤其在采用减低强度预处理方案时更为显著，且由于挽救治疗方案疗效有限，复发仍是导致这些患者治疗失败的主要原因。因此，亟需制定降低复发风险的策略。过去几年中，多项针对靶向治疗、化疗及免疫调节治疗的临床试验，初步构建了移植后维持治疗的基本框架。尽管AML移植后维持治疗的应用日益普遍，但该策略在可行性与疗效方面仍面临诸多挑战。本文综述了AML移植后维持治疗的主要进展，以及该领域正在进行和计划开展的研究，并指出当前数据的局限性及未来的研究方向。

原文链接：

Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia